Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis-Reference-Cited by-同舟云学术

Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis

Published:2018-11-19 Issue:6 Volume:68 Page:2145-2157
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Gane Edward J.¹,Stedman Catherine A.²,Schwabe Christian¹,Vijgen Leen³,Chanda Sushmita⁴,Kakuda Thomas N.⁴^ORCID,Fry John⁴,Blatt Lawrence M.⁴,McClure Matthew W.⁴

Affiliation:

1. Auckland Clinical Studies; Auckland New Zealand

2. Christchurch Hospital and University of Otago; Christchurch New Zealand

3. Janssen Research & Development; Janssen Pharmaceutica NV; Beerse Belgium

4. Alios BioPharma Inc. part of the Janssen Pharmaceutical Companies; South San Francisco California

Funder

Alios BioPharma Inc.

Complete Medical Communications

Janssen Pharmaceutical

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.30126/fullpdf

Reference29 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;The Polaris Observatory HCV collaborators;Lancet Gastroenterol Hepatol,2017

2. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality;Cramp;BMC Gastroenterol,2014

3. American Association for the Study of Liver Diseases, Infectious Diseases Society of America HCV guidance: recommendations for testing, managing and treating hepatitis C https://www.hcvguidelines.org/ 2017

4. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis;Kwo;J Hepatol,2017

5. Desirable characteristics of hepatitis C treatment regimens: a review of what we have and what we need;Bidell;Infect Dis Ther,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a Commercial Process for Odalasvir;Organic Process Research & Development;2021-12-15

2. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03

3. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting;Journal of Viral Hepatitis;2021-01-02

4. Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study;Journal of Medical Virology;2020-11-22

5. Therapeutic siRNA: state of the art;Signal Transduction and Targeted Therapy;2020-06-19